Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020254 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020254: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00020254 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020254, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill prostate cancer cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using nilutamide may fight prostate cancer by reducing the production of androgens. It is not yet known which treatment regimen is more effective for treating prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy plus sargramostim and interleukin-2 with that of nilutamide alone in treating patients who have prostate cancer that has not responded to hormone therapy.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL sargramostim
- BIOLOGICAL recombinant fowlpox-prostate specific antigen vaccine
- BIOLOGICAL recombinant vaccinia prostate-specific antigen vaccine
- BIOLOGICAL recombinant vaccinia-B7.1 vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020254
The ClinicalTrials.gov registry entry for NCT00020254 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which aldesleukin is the first listed.
NCT00020254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020254 about?
NCT00020254 is a clinical study titled "Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer". RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cel...
What is the current status of trial NCT00020254?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06.
What interventions are being tested in trial NCT00020254?
The interventions under investigation include: aldesleukin (BIOLOGICAL), sargramostim (BIOLOGICAL), recombinant fowlpox-prostate specific antigen vaccine (BIOLOGICAL), recombinant vaccinia prostate-specific antigen vaccine (BIOLOGICAL), recombinant vaccinia-B7.1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00020254?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.